NEO Stock Analysis: NeoGenomics | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 1.854m USD | 12M Return: 88.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 41.2M
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
NeoGenomics, Inc. (NEO) is a specialty diagnostics company that operates a network of cancer-focused testing laboratories across the United States and the United Kingdom. Founded in 2001 and headquartered in Fort Myers, Florida, the company provides a broad menu of oncology-related testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical firms, and other clinical laboratories. Its service offerings span cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry with digital imaging, molecular testing, and morphologic analysis, and it also supports pharmaceutical clients oncology drug discovery and commercialization programs.
As a small-cap player in the Health Care Services sub-industry, NeoGenomics operates within the outsourced clinical diagnostics sector, where independent labs perform complex, specialized tests on behalf of hospitals and physicians rather than the tests being conducted in-house. Its focus on oncology makes it a niche provider in a broader U.S. clinical laboratory market that also includes larger, diversified competitors.
- Pharma services revenue accelerates with oncology clinical trial demand
- Medicare reimbursement cuts pressure clinical testing margins
- Competition intensifies from liquid biopsy and molecular diagnostic peers
| Net Income: -99.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 1.64 > 1.0 |
| NWC/Revenue: 38.75% < 20% (prev 43.76%; Δ -5.01% < -1%) |
| CFO/TA 0.02 > 3% & CFO 22.4m > Net Income -99.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.8m) vs 12m ago 1.41% < -2% |
| Gross Margin: 42.13% > 18% (prev 44.30%; Δ -2.17% > 0.5%) |
| Asset Turnover: 50.61% > 50% (prev 41.99%; Δ 8.62% > 0%) |
| Interest Coverage Ratio: -36.61 > 6 (EBIT TTM -100.1m / Interest Expense TTM 2.73m) |
| A: 0.21 (Total Current Assets 373.7m - Total Current Liabilities 84.6m) / Total Assets 1.35b |
| B: -0.33 (Retained Earnings -450.9m / Total Assets 1.35b) |
| C: -0.07 (EBIT TTM -100.1m / Avg Total Assets 1.47b) |
| D: 1.60 (Book Value of Equity 828.8m / Total Liabilities 517.8m) |
| Altman-Z'' = 1.54 = BB |
| DSRI: 1.00 (Receivables 167.4m/151.2m, Revenue 746.0m/672.4m) |
| GMI: 1.05 (GM 44.30% / 42.13%) |
| AQI: 1.12 (AQ_t 0.60 / AQ_t-1 0.54) |
| SGI: 1.11 (Revenue 746.0m / 672.4m) |
| TATA: -0.09 (NI -99.2m - CFO 22.4m) / TA 1.35b) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 14.11 with a total of 1,353,993 shares traded. Over the past week, the price has changed by -6.93%, over one month by +25.09%, over three months by +83.49% and over the past year by +88.38%.
Current recommended Stop Loss: 13.20 (which is 6.4% or 1.3 ATR below the current price).
NeoGenomics has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy NEO.
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.1 | 7.1% |
P/E Forward = 222.2222
P/S = 2.4856
P/B = 2.3819
P/EG = 2.0871
Revenue TTM = 746.0m USD
EBIT TTM = -100.1m USD
EBITDA TTM = -33.5m USD
Long Term Debt = 342.2m USD (from longTermDebt, last quarter)
Short Term Debt = 4.83m USD (from shortTermDebt, last quarter)
Debt = 474.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 66.3m
Net Debt = 328.7m USD (calculated: Debt 474.8m - CCE 146.1m)
Enterprise Value = 2.18b USD (1.85b + Debt 474.8m - CCE 146.1m)
Interest Coverage Ratio = -36.61 (Ebit TTM -100.1m / Interest Expense TTM 2.73m)
EV/FCF = -429.0x (Enterprise Value 2.18b / FCF TTM -5.09m)
FCF Yield = -0.23% (FCF TTM -5.09m / Enterprise Value 2.18b)
FCF Margin = -0.68% (FCF TTM -5.09m / Revenue TTM 746.0m)
Net Margin = -13.30% (Net Income TTM -99.2m / Revenue TTM 746.0m)
Gross Margin = 42.13% ((Revenue TTM 746.0m - Cost of Revenue TTM 431.7m) / Revenue TTM)
Gross Margin QoQ = 43.32% (prev 39.81%)
Tobins Q-Ratio = 1.62 (Enterprise Value 2.18b / Total Assets 1.35b)
Interest Expense / Debt = 0.58% (Interest Expense 2.73m / Debt 474.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -79.0m (EBIT -100.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.42 (Total Current Assets 373.7m / Total Current Liabilities 84.6m)
Debt / Equity = 0.57 (Debt 474.8m / totalStockholderEquity, last quarter 828.8m)
Debt / EBITDA = -9.80 (negative EBITDA) (Net Debt 328.7m / EBITDA -33.5m)
Debt / FCF = -64.60 (negative FCF - burning cash) (Net Debt 328.7m / FCF TTM -5.09m)
Total Stockholder Equity = 839.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.73% (Net Income -99.2m / Total Assets 1.35b)
RoE = -11.82% (Net Income TTM -99.2m / Total Stockholder Equity 839.4m)
RoCE = -8.47% (EBIT -100.1m / Capital Employed (Equity 839.4m + L.T.Debt 342.2m))
RoIC = -6.43% (negative operating profit) (NOPAT -79.0m / Invested Capital 1.23b)
WACC = 6.97% (E(1.85b)/V(2.33b) * Re(8.64%) + D(474.8m)/V(2.33b) * Rd(0.58%) * (1-Tc(0.21)))
Discount Rate = 8.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 1.13%
[DCF] Fair Price = unknown (Cash Flow -5.09m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: 99.74 | Revenue CAGR: 11.12% | SUE: 0.71 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.03 | Chg30d=N/A | Revisions=-25% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.05 | Chg30d=+0.00% | Revisions=+0% | Analysts=11
EPS current Year (2026-12-31): EPS=0.18 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+50.0% | GrowthRev=+10.1%
EPS next Year (2027-12-31): EPS=0.36 | Chg30d=+0.00% | Revisions=+44% | GrowthEPS=+102.5% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: +14% (up=11, down=8)